(CercleFinance.com) – AstraZeneca announced on Monday that the Committee for Medicinal Products for Human Use (CHMP), an offshoot of the European Medicines Agency, had recommended the marketing of several of its products, including its new anti-asthmatic Tezspire .
The committee issued a positive opinion for the marketing, both in the context of the treatment of asthma and that of severe asthma, of this monoclonal antibody developed with Amgen and already marketed in the United States.
The CHMP also recommended that Ultomiris be authorized for the treatment of patients with generalized myasthenia gravis, a potentially life-threatening weakness of the respiratory muscles.
It should also be noted that the American FDA has decided to grant a priority review to the examination of Enhertu concerning the treatment of metastatic breast cancer with low expression of HER2.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
